Macromolecular anticancer therapeutics
著者
書誌事項
Macromolecular anticancer therapeutics
（Cancer drug discovery and development）
Springer Verlag, 2009
大学図書館所蔵 件 / 全1件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
内容説明・目次
内容説明
In spite of the development of various anticancer drugs, the therapy of cancer has remained challenging for decades. The current therapy of cancer is overwhelmed because of the inability to deliver therapeutics to all regions of a tumor in effective therapeutic concentrations, intrinsic or acquired resistance to the treatment with currently available agents via genetic and epigenetic mechanisms, and toxicity. As a result, cancer therapy using conventional therapeutics and different types of treatment regimens using this therapeutics has not led to a convincing survival benefit of the patients. In this context, Macromolecular therapeutics offer several advantages over conventional low molecular therapeutics by various ways such as, enable the use of larger doses of these agents by limiting the toxicity, by enhanced permeability and retention into tumors, by tumor targeting using tumor-specific antibodies, by specific inhibition of oncogenes using anticancer oligonucleotides etc. Cancer treatment using this macromolecular therapeutics has considerably improved the survival benefit for patients. As a result, various macromolecular therapeutics are already commercialized or are under clinical development. Although we are far from a real magic bullet today, looking at the pace of research and current success in this field of macromolecular therapeutics, it appears that we are approaching a magic bullet for the efficient treatment of cancer. Thus, we believe that the subject of this book is very timely, and that the book will fill an unmet need in the market.
This book is unique and assembles various types and aspects of macromolecular anticancer therapeutics for cancer therapy in one shell and conveys the importance of this interdisciplinary field to the broad audience. Thus, in a nutshell, this book details the basics of cancer, and various therapeutic strategies such as those based on macromolecular therapeutics hence can become an important reference for practitioners, oncologists, medical pharmacologists, medicinal chemists, biomedical scientists, experimental pharmacologists, pharmaceutical technologists, and particularly it can essentially become a handbook of macromolecular therapeutics for cancer therapy for graduates, post-graduates and Ph.D. students in these fields.
目次
- I. Synthetic polymer-based anticancer prodrugs Jindrich Kopecek (Departments of Pharmaceutics and Pharmaceutical Chemistry and of Bioengineering, University of Utah, Salt Lake City, Utah 84112) HPMA-anticancer drug conjugates Richard B. Greenwald (Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey 00854) Poly(ethylene glycol)-anticancer drug conjugates Chun Li (Department of Experimental Diagnostic Imaging, Box 59, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA) Poly(L-glutamic acid)-anticancer drug conjugates II. Natural polymer-based anticancer prodrugs Felix Kratz (Department of Medical Oncology, Clinical Research, Tumor Biology Center, Breisacher Strasse 117, D-79106 Freiburg, Federal Republic of Germany) Protein-based anticancer conjugates Andrew V. Schally (Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana) Peptide and peptide hormone anticancer therapeutics Yoshiharu Machida (Department of Drug Delivery Research, Hoshi University
- 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan) Chitosan and other polysaccharide anticancer conjugates III. Antibody-directed cancer therapy John R. Desjarlais Xencor, Inc. CA 91016, United States Engineering of antitumor antibodies Victor S. Goldmacher (ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA) Antibody-anticancer drug conjugates David M. Goldenberg (Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA.) Immunoconjugate and radioimmunoconjugate anticancer therapeutics Kenneth D. Bagshawe (Imperial College London, Department of Medical Oncology, Charing Cross Campus, Fulham Palace Road, London W6 8RF, UK.) Antibody-directed enzyme prodrug anticancer therapeutics Paul M. Harari (University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, WI 53792, USA.) EGFR-directed monoclonal antibodies Gabriel N. Hortobagyi (Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX. usa) Her2/neu-directed antibodies John M. Kirkwood (Division of Hematology-Oncology, Department of Medicine, Hillman Cancer Center, Pittsburgh, PA 15232) CTLA-4-directed monoclonal antibodies Dario Neri (Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland) Antibodies directed to tumor vasculature IV. Lipid-based anticancer prodrugs L. Harivardhan Reddy, Patrick Couvreur (Physicochimie, Pharmacotechnie et Biopharmacie, Faculty of Pharmacy, Universite Paris-Sud XI, Chatenay-Malabry, France) Lipid-based prodrugs of anti-metabolite anticancer agents Mitsuru Hashida (Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan) Lipid-based prodrugs of non-anti-metabolite anticancer agents V. Macromolecular nucleic acid therapeutics Ernst Wagner (Pharmaceutical Biology-Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universitaet, Butenandtstr. 5-13, D-81377, Muenchen, Germany) Macromolecular nucleic acid therapeutics Uwe Zangemeister-Wittke (Department of Pharmacology, University of Bern, Bern, Switzerland.) Antisense oligonucleotides Brett P. Monia (Isis Pharmaceuticals, California 92008, USA) Therapeutic MicroRNAs Mark A. Behlke (Integrated DNA Technologies Inc., Coralville, IA 52241, USA) Therapeutic siRNAs
「Nielsen BookData」 より